Specialty pipeline milestones
Teva Pharmaceutical (TEVA) has been actively involved in multiple research programs in its specialty pipeline. They include research in multiple sclerosis (or MS), movement disorders, and neurodegeneration, pain, and respiratory.
In 3Q16, Teva expects the FDA (U.S. Food and Drug Administration) to approve its pain management and abuse deterrent opioid drug Vantrela. If that happens, Teva may see a strong rise in share prices. It may also boost the VanEck Vectors Pharmaceutical ETF (PPH). Teva Pharmaceutical makes up about 4.4% of PPH’s total portfolio holdings.
MS, movement disorders, and neurodegeneration
Teva Pharmaceutical expects to obtain FDA approval for SD-809 for the treatment of chorea associated with Huntington’s disease by March 2017. The company plans to give a full response to the complete response letter from the FDA by September 2016.
Teva also expects Phase 3 results for the use of SD-809 for tardive dyskinesia and Phase 2 results for pridopidine for Huntington’s disease. Similar to Alexion Pharmaceuticals (ALXN), Amgen (AMGN), and Celgene (CELG), Teva Pharmaceutical has been actively involved in developing therapies targeted at orphan diseases. To know more about Teva’s orphan disease strategy, please refer to Why Has Teva Pharmaceutical Targeted Orphan Diseases?
On June 7, 2016, Teva Pharmaceutical (TEVA) received a recommendation from the FDA Advisory Committee for the approval of its pain management and abuse deterrent opioid drug Vantrela. The company expects to obtain FDA approval for the drug in 3Q16.
Teva also expects to release Phase 3 data related to its pain segment drug TV-46763. To know more about these drugs, please refer to How Is Teva Aiming to Lead the Abuse-Deterrent Opioid Segment?
Teva Pharmaceutical has projected that in 3Q16, it will receive two regulatory approvals for its investigational respiratory drugs reslizumab and Fluticasone/Salmeterol Spiromax in Europe. To know more about Teva’s respiratory research programs, please refer to Teva’s Asthma Segment: What Could Boost Its Revenues in 2016?